Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00403767 · ClinicalTrials.gov registry record · Phase 3
An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation
A Phase 3 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 3
- Development phase
- 14,269
- Enrollment target
NCT00403767 is a Phase 3 study that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 14,269 participants.
The verdict
NCT00403767, a Phase 3 study, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 14,269 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy and safety of rivaroxaban with warfarin for the prevention of blood clots in the brain (referred to as stroke) and blood clots in other parts of the body referred to as non-central nervous system systemic embolism) in patients with non-valvular atrial fibrillation (a heart rhythm disorder).
Interventions
- DRUG Warfarin
- DRUG Rivaroxaban
- DRUG Matching placebo for Rivaroxaban arm (Warfarin placebo)
- DRUG Matching placebo for Warfarin arm (Rivaroxaban placebo)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14,269 participants |
| Start Date | 2006-12 |
| Est. Completion | 2010-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00403767
The ClinicalTrials.gov registry entry for NCT00403767 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 14,269 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Warfarin is the first listed.
NCT00403767 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00403767 about?
NCT00403767 is a clinical study titled "An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation". The purpose of this study is to compare the efficacy and safety of rivaroxaban with warfarin for the prevention of blood clots in the brain (referred to as stroke) and blood clots in other parts of the body referred to as non-central nervous system systemic embolism) in patients with non-valvular at...
What is the current status of trial NCT00403767?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 14,269 participants. The study started on 2006-12. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00403767?
The interventions under investigation include: Warfarin (DRUG), Rivaroxaban (DRUG), Matching placebo for Rivaroxaban arm (Warfarin placebo) (DRUG), Matching placebo for Warfarin arm (Rivaroxaban placebo) (DRUG).
Who is sponsoring clinical trial NCT00403767?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.